Second-Half Vascepa Sales Growth Still in Focus for Amarin (AMRN); Aegis Maintains at 'Hold'
Get Alerts AMRN Hot Sheet
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Aegis Capital maintains its Hold rating and $2 price target on Amarin Corp. (Nasdaq: AMRN) following Q1 results reported last week.
Analyst Ram Selvaraju Vascepa sales came in lighter than expected at $1.1 million, though R&D expenses of $11.7 million compared with the analysts expectation of $14 million. Overall, this was an in-line quarter, with the firm recording a net loss of $0.15, as we had originally projected. We have gradually reduced our revenue expectations for Vascepa from $68mm to $66mm, in anticipation of sales growth in the second half of 2014 driven by the co-promotion arrangement with Kowa. The sales reps from Kowa are slated to begin promoting Vascepa this month,
the analyst said.
FY14 revenue and loss outlook move from $68 million and $.46 per share to $66 million and $.40 per share.
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $1.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amazon.com (AMZN) PT Raised to $215 at UBS
- MarineMax (HZO) PT Lowered to $35 at Stifel
- Macquarie Upgrades ASM Pacific Technology (522:HK) (ASMVY) to Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!